Skip to main content

Goldsmith Mark A's Form 4 filing

Revolution Medicines, Inc. (RVMD) · filed Apr 17, 2026

Accession no.
0001610717-26-000146
Filed
Apr 17, 2026
Trade date
Apr 15, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $18.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Goldsmith Mark ACIK 0001246842Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 15, 2026Common StockMOption exerciseAcquired+23,244$4.09+$95,067.96299,942Direct
Apr 15, 2026Common StockMOption exerciseAcquired+96,756$4.73+$457,655.88396,698Direct
Apr 15, 2026Common StockSSaleDisposed−120,000$150.09F3−$18,010,800276,698Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 15, 2026Common StockMOption exerciseDisposed−23,244$0.00$024,464Direct
Apr 15, 2026Common StockMOption exerciseDisposed−96,756$0.00$0424,085Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

This transaction was executed in multiple trades at prices ranging from $150.00 to $150.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

President and Chief Executive Officer

Read the full filing on SEC EDGAR (opens in a new tab)